Last Updated: November 10, 2026

Details for Patent: 12,285,422

Name: Drug Patent Intelligence for US Patent 12285422
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 12,285,422 protect, and when does it expire?

Patent 12,285,422 protects FABHALTA and is included in one NDA.

This patent has fifty patent family members in twenty-two countries.

Summary for Patent: 12,285,422

Title:	Uses of piperidinyl-indole derivatives
Abstract:	The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment of patients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).
Inventor(s):	Jorg Eder, Richard Alexander Harrison, Boerje Haraldsson, Anna Svenja Shchubart Wellensiek
Assignee:	Novartis AG , Novartis Pharma AG
Application Number:	US17/589,281
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,285,422

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	FABHALTA	iptacopan hydrochloride	CAPSULE;ORAL	218276-001	Dec 5, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 12,285,422

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018326768	⤷ Start Trial
Brazil	112020003737	⤷ Start Trial
Canada	3073346	⤷ Start Trial
Chile	2020000483	⤷ Start Trial
China	111032042	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.